The publication of this infographic was initiated and funded by Bristol Myers Squibb, who did not create the content.
A 2025 EHA guideline for managing large B-cell lymphoma includes new recommendations for CAR T-cell therapy in patients who relapse within 12 months of 1L treatment. Our infographic summarizes the new guidance and treatment eligibility criteria.
Topics covered include:
- New EHA recommendations for 1L, 2L and 3L treatment of LBCL
- How to stratify patients for 2L CAR T.
- Recommendations for diagnosis and disease monitoring.
